ii This approval underscores GSK's commitment to help drive progress for people living with complex blood cancers.

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it “frustrating” that despite the favorable Zantac settlement, robust ...

GSK (GSK) plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization, STAT’s John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Kirkland & Ellis has backed a U.K.-based energy infrastructure group and U.S.-based private equity firm through ... according ...

AI-enhanced manufacturing applications are now being deployed around the world as a massive upgrade in efficiency.

(Reuters) -Haleon posted an unexpected drop in third-quarter revenue on Thursday, hurt by a weak demand for its painkiller in ...

The pharmaceutical giant reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance ...